Overview

Time of Intravenous Acetaminophen Administration

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to examine the effects of timing of administration of intravenous (IV) acetaminophen and how timing relates to analgesic efficacy as measured by postoperative pain scores. A maximum of 138 patients meeting inclusion criteria who present for a scheduled total hip replacement under general anesthesia will be randomized into one of two arms: 1) the pre-closure group will receive the first dose administered upon onset of skin closure, 2) the preemptive group will receive the first dose administered within 60 minutes prior to incision. Both groups will receive subsequent doses every 6 hours x 24 hours.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Duke University
Treatments:
Acetaminophen
Criteria
Inclusion Criteria:

- Patients 30-75 years of age weighing ≥55 kg scheduled for elective total hip
arthroplasty performed under general anesthesia will be included. As determined by the
anesthesia team assigned to the case, eligible patients will also be assigned ASA
physical status of I, II, or III and deemed capable of reporting their perceived pain
using numeric pain scales and capable of operating a patient controlled anesthesia
(PCA) device.

Exclusion Criteria:

- Exclusion criteria include known allergy, hypersensitivity, or contraindication to
acetaminophen, history of alcohol or drug abuse, prisoners, emergency THAs, patients
with chronic malnutrition or a body mass index (BMI) < 18 kg/m2 and non-English
speaking patients. Additional exclusion criteria include impaired liver function
defined as AST and ALT each ≥ twice normal limits and renal dysfunction (creatinine
>2.0 mg/dl).